Steven De Vleeschouwer

List of Publications by Year
in descending order

72 papers	3,615 citations	172457 29 h-index	144013 57 g-index
80 all docs	80 docs citations	80 times ranked	4651 citing authors

#	Article	IF	Citations
1	Gliomas: Diffusion Kurtosis MR Imaging in Grading. Radiology, 2012, 263, 492-501.	7.3	311
2	Single-cell profiling of myeloid cells in glioblastoma across species and disease stage reveals macrophage competition and specialization. Nature Neuroscience, 2021, 24, 595-610.	14.8	288
3	Postoperative Adjuvant Dendritic Cellâ€“Based Immunotherapy in Patients with Relapsed Glioblastoma Multiforme. Clinical Cancer Research, 2008, 14, 3098-3104.	7.0	237
4	Newcastle disease virotherapy induces longâ€term survival and tumorâ€specific immune memory in orthotopic glioma through the induction of immunogenic cell death. International Journal of Cancer, 2015, 136, E313-25.	5.1	165
5	Surgery and adjuvant dendritic cell-based tumour vaccination for patients with relapsed malignant glioma, a feasibility study. British Journal of Cancer, 2004, 91, 1656-1662.	6.4	161
6	Integration of autologous dendritic cell-based immunotherapy in the standard of care treatment for patients with newly diagnosed glioblastoma: results of the HGG-2006 phase I/II trial. Cancer Immunology, Immunotherapy, 2012, 61, 2033-2044.	4.2	136
7	Formulations for Intranasal Delivery of Pharmacological Agents to Combat Brain Disease: A New Opportunity to Tackle GBM?. Cancers, 2013, 5, 1020-1048.	3.7	126
8	Trial watch: dendritic cell vaccination for cancer immunotherapy. OncoImmunology, 2019, 8, 1638212.	4.6	125
9	Development of siRNA-loaded chitosan nanoparticles targeting Galectin-1 for the treatment of glioblastoma multiforme via intranasal administration. Journal of Controlled Release, 2016, 227, 71-81.	9.9	123
10	Adjuvant dendritic cellâ€based tumour vaccination for children with malignant brain tumours. Pediatric Blood and Cancer, 2010, 54, 519-525.	1.5	120
11	Integration of autologous dendritic cell-based immunotherapy in the primary treatment for patients with newly diagnosed glioblastoma multiforme: a pilot study. Journal of Neuro-Oncology, 2010, 99, 261-272.	2.9	119
12	Sensitization of glioblastoma tumor micro-environment to chemo- and immunotherapy by Galectin-1 intranasal knock-down strategy. Scientific Reports, 2017, 7, 1217.	3.3	105
13	DC vaccination with anti-CD25 treatment leads to long-term immunity against experimental glioma. Neuro-Oncology, 2009, 11, 529-542.	1.2	94
14	Dendritic Cell Therapy of Highâ€Grade Gliomas. Brain Pathology, 2009, 19, 694-712.	4.1	90
15	MR perfusion and diffusion imaging in the follow-up of recurrent glioblastoma treated with dendritic cell immunotherapy: a pilot study. Neuroradiology, 2011, 53, 721-731.	2.2	72
16	Gliomaâ€derived galectinâ€1 regulates innate and adaptive antitumor immunity. International Journal of Cancer, 2014, 134, 873-884.	5.1	71
17	Galectin-1 in Melanoma Biology and Related Neo-Angiogenesis Processes. Journal of Investigative Dermatology, 2012, 132, 2245-2254.	0.7	64
18	Preclinical efficacy of immune-checkpoint monotherapy does not recapitulate corresponding biomarkers-based clinical predictions in glioblastoma. OncoImmunology, 2017, 6, e1295903.	4.6	64

#	Article	IF	Citations
19	DENDRITIC CELL VACCINATION IN PATIENTS WITH MALIGNANT GLIOMAS. Neurosurgery, 2006, 59, 988-1000.	1.1	61
20	Transient local response and persistent tumor control in a child with recurrent malignant glioma: treatment with combination therapy including dendritic cell therapy. Journal of Neurosurgery: Pediatrics, 2004, 100, 492-497.	1.3	56
21	Primary brain tumours, meningiomas and brain metastases in pregnancy: Report on 27 cases and review of literature. European Journal of Cancer, 2014, 50, 1462-1471.	2.8	54
22	Dynamic stroma reorganization drives blood vessel dysmorphia during glioma growth. EMBO Molecular Medicine, 2017, 9, 1629-1645.	6.9	54
23	Trial watch: Dendritic cell (DC)-based immunotherapy for cancer. OncoImmunology, 2022, 11, .	4.6	54
24	Living with a high-grade glioma: A qualitative study of patients' experiences and care needs. European Journal of Oncology Nursing, 2015, 19, 383-390.	2.1	51
25	What the neurosurgeon should know about hemangioblastoma, both sporadic and in Von Hippel-Lindau disease: A literature review. , 2013, 4, 145.		51
26	Irradiation of necrotic cancer cells, employed for pulsing dendritic cells (DCs), potentiates DC vaccine-induced antitumor immunity against high-grade glioma. OncoImmunology, 2016, 5, e1083669.	4.6	49
27	Defining pseudoprogression in glioblastoma multiforme. European Journal of Neurology, 2013, 20, 1335-1341.	3.3	48
28	SLIT2/ROBO signaling in tumor-associated microglia and macrophages drives glioblastoma immunosuppression and vascular dysmorphia. Journal of Clinical Investigation, 2021, 131, .	8.2	46
29	Uptake and presentation of malignant glioma tumor cell lysates by monocyte-derived dendritic cells. Cancer Immunology, Immunotherapy, 2005, 54, 372-382.	4.2	42
30	Altered galectin-1 serum levels in patients diagnosed with high-grade glioma. Journal of Neuro-Oncology, 2013, 115, 9-17.	2.9	42
31	Risk Analysis of Thrombo-Embolic and Recurrent Bleeding Events in the Management Of Intracranial Haemorrhage Due to Oral Anticoagulation. Acta Chirurgica Belgica, 2005, 105, 268-274.	0.4	39
32	DNA methylation based glioblastoma subclassification is related to tumoral T-cell infiltration and patient survival. Neuro-Oncology, 2021, 23, 240-250.	1.2	31
33	Glioblastoma: To Target the Tumor Cell or the Microenvironment?. , 0, , 315-340.		31
34	Effect of awake craniotomy in glioblastoma in eloquent areas (GLIOMAP): a propensity score-matched analysis of an international, multicentre, cohort study. Lancet Oncology, The, 2022, 23, 802-817.	10.7	31
35	Persistent IL-10 production is required for glioma growth suppressive activity by Th1-directed effector cells after stimulation with tumor lysate-loaded dendritic cells. Journal of Neuro-Oncology, 2007, 84, 131-140.	2.9	28
36	Development and validation of a fully GMP-compliant production process of autologous, tumor-lysate-pulsed dendritic cells. Cytotherapy, 2014, 16, 946-964.	0.7	27

#	Article	IF	Citations
37	Family Caregivers of Patients With a High-Grade Glioma. Cancer Nursing, 2015, 38, 406-413.	1.5	26
38	Immunotherapy for malignant gliomas: emphasis on strategies of active specific immunotherapy using autologous dendritic cells. Child's Nervous System, 2005, 21, 7-18.	1.1	25
39	Immune Suppression during Oncolytic Virotherapy for High-Grade Glioma; Yes or No?. Journal of Cancer, 2015, 6, 203-217.	2.5	24
40	Immunogenic cell death and its therapeutic or prognostic potential in high-grade glioma. Genes and Immunity, 2022, 23, 1-11.	4.1	24
41	Galectin-1 and immunotherapy for brain cancer. Expert Review of Neurotherapeutics, 2011, 11, 533-543.	2.8	23
42	Stratification according to HGG-IMMUNO RPA model predicts outcome in a large group of patients with relapsed malignant glioma treated by adjuvant postoperative dendritic cell vaccination. Cancer Immunology, Immunotherapy, 2012, 61, 2105-2112.	4.2	23
43	Characterization of PDâ€1 upregulation on tumorâ€infiltrating lymphocytes in human and murine gliomas and preclinical therapeutic blockade. International Journal of Cancer, 2017, 141, 1891-1900.	5.1	23
44	Technical advancement in regulatory T cell isolation and characterization using CD127 expression in patients with malignant glioma treated with autologous dendritic cell vaccination. Journal of Immunological Methods, 2010, 352, 169-173.	1.4	22
45	Optimized preoperative motor cortex mapping in brain tumors using advanced processing of transcranial magnetic stimulation data. NeuroImage: Clinical, 2019, 21, 101657.	2.7	16
46	Safe surgery for glioblastoma: Recent advances and modern challenges. Neuro-Oncology Practice, 2022, 9, 364-379.	1.6	14
47	The incidence of postoperative cerebrospinal fluid leakage after elective cranial surgery: a systematic review. Neurosurgical Review, 2022, 45, 1827-1845.	2.4	13
48	Ependymomas of the filum terminale: The role of surgery and radiotherapy. , 2012, 3, 76.		12
49	Re-irradiation or re-operation followed by dendritic cell vaccination? Comparison of two different salvage strategies for relapsed high-grade gliomas by means of a new prognostic model. Journal of Neuro-Oncology, 2015, 124, 325-332.	2.9	10
50	Long-lasting, Complete Exclusion of a Large Galenic Dural Arteriovenous Fistula After Clipping of the Central Venous Aneurysm of the Vein of Galen: Case Report. Neurosurgery, 2011, 68, E571-E574.	1.1	9
51	Results of endoscopic third ventriculostomy in elderly patients â‰¥65 years of age. Clinical Neurology and Neurosurgery, 2015, 130, 48-54.	1.4	8
52	5-Aminolevulinic acid for recurrent malignant gliomas: A systematic review. Clinical Neurology and Neurosurgery, 2020, 195, 105913.	1.4	8
53	Resection and Immunotherapy for Recurrent Grade III Glioma. ISRN Immunology, 2012, 2012, 1-9.	0.7	8
54	Should dendritic cell-based tumor vaccination be incorporated into standard therapy for newly diagnosed glioblastoma patients?. Expert Review of Neurotherapeutics, 2012, 12, 1173-1176.	2.8	7

#	Article	IF	Citations
55	Screening for Intracranial Aneurysms in Individuals with a Positive First-Degree Family History: A Systematic Review. World Neurosurgery, 2021, 151, 235-248.e5.	1.3	7
56	Towards real-time intraoperative tissue interrogation for REIMS-guided glioma surgery. Journal of Mass Spectrometry and Advances in the Clinical Lab, 2022, 24, 80-89.	2.4	7
57	Global comparison of awake and asleep mapping procedures in glioma surgery: An international multicenter survey. Neuro-Oncology Practice, 2022, 9, 123-132.	1.6	6
58	Dendritic cell vaccination for glioblastoma multiforme: review with focus on predictive factors for treatment response. ImmunoTargets and Therapy, 2014, 3, 55.	5.8	5
59	Recurring Glioblastoma: A Case for Reoperation?. , 0, , 281-296.		5
60	Letter: Maximizing the extent of resection and survival benefit of patients in glioblastoma surgery: High-field iMRI versus conventional and 5-ALA-assisted surgery. European Journal of Surgical Oncology, 2014, 40, 1384-1385.	1.0	3
61	Automated speech analysis to improve TMS-based language mapping: Algorithm and proof of concept. Brain Stimulation, 2020, 13, 267-269.	1.6	3
62	Maximizing extent of resection while minimizing the risk of neurological morbidity in glioma patients: a novel grading scale to translate these surgical goals into a merged onco-functional clinical outcome. Neuro-Oncology, 2021, 23, 504-505.	1.2	3
63	Irradiation of necrotic tumor cells used to pulse dendritic cells (DCs) potentiates DC vaccine-induced anti-tumor immunity in a mouse model of high-grade glioma. , 2014, 2, .		1
64	A posttraumatic pontomedullary rent with good outcome. Acta Neurochirurgica, 2016, 158, 577-579.	1.7	1
65	Intracerebral abscess due to Cutibacterium acnes after lung transplantation. Transplant Infectious Disease, 2021, 23, e13398.	1.7	1
66	Stroke rate after external fractionated radiotherapy for benign meningioma. Journal of Neuro-Oncology, 2021, 152, 99-106.	2.9	1
67	Treatment of ruptured subclavian steal flow-related vertebrobasilar junction aneurysms: Case report on surgical and endovascular considerations from two cases. International Journal of Surgery Case Reports, 2022, 90, 106744.	0.6	1
68	Adjuvant dendritic cell-based tumor vaccination for children with malignant brain tumors: preliminary results. World Neurosurgery, 2009, 71, 135.	1.3	0
69	36 Clinical applications â€“ lessons from pediatrics. European Journal of Cancer, Supplement, 2009, 7, 12.	2.2	0
70	High-Grade Gliomas: Dendritic Cell Therapy. , 2011, , 313-333.		0
71	Dendritic cell vaccination for glioblastoma multiforme: Clinical experience and future directions. , 2014, , .		0
72	MGMT promoter methylation and IDH1 mutation as prognostic markers for a favorable clinical outcome in patients with glioblastoma multiforme.. Journal of Clinical Oncology, 2010, 28, 2053-2053.	1.6	0